Inovio Pharmaceuticals, Inc. (NASDAQ:INO) reported Sales of 37.6 Million

Ivan Schwartz
June 14, 2017

Trading of shares of Inovio Pharmaceuticals (NASDAQ:INO) will be interesting to watch this afternoon as Piper Jaffray upped the stock to a Buy. (NASDAQ:INO)'s stock was 16.71%. Maxim Group's price target would indicate a potential upside of 48.15% from the company's current price.

Other research analysts have also issued research reports about the company. Brean Capital maintained the stock with "Buy" rating in Monday, March 14 report. Comparatively, Inovio Pharmaceuticals, Inc. posted earnings of $-0.15 per share in the same quarter previous year.

Among 5 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 5 have Buy rating, 0 Sell and 0 Hold.

05/24/2017 - Inovio Pharmaceuticals, Inc. had its " rating reiterated by analysts at Maxim Group. The rating has been disclosed in analysts note on Thursday, 8 June. "Ultimately, through all this investigation into the company's performance the analyst decides if their stock is a "buy", sell" or hold". (INO) now has a value of $8.1 while the company's 52 week low is at $5.83, the shares dropped to the 52 week low on 03/22/17. Inovio Pharmaceuticals, Inc.'s average EBITDA per Share Growth Rate was 0 percent during the past 12 months. Earnings per share serves as an indicator of a company's profitability. The market capitalization of the company is at $600.64 Million. Inovio Pharmaceuticals has a 1-year low of $5.83 and a 1-year high of $11.62.

Trump calls Comey "cowardly" as more questions on Russian Federation loom in Congress
Adam Schiff, sent a formal request to the White House for any records of Trump's private meetings with Comey. House Russia investigators, led by Texas Republican Rep.

NBA Finals 2017: Kevin Durant, mother Wanda celebrate after Warriors clinch title
Other teams - teams that aren't the favorites to play for the title next year - they're going to have to get creative, and quick. Cleveland's bench has just four points. "So I would hope we're more ready, more prepared tonight". "We have to be more on edge".

Hungary passes bill regulating foreign-funded NGOs
Mass protests have broken out across Hungary in recent months in the wake of the new NGO and university laws. However, Human Rights Watch (HRW) dismissed the amendments as "cosmetic".

Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Up in the future.

It is down 29.01% since June 13, 2016 and is downtrending. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.31).

05/18/2015 - Inovio Pharmaceuticals, Inc. was upgraded to " by analysts at Zacks. The business's revenue for the quarter was up 28.4% compared to the same quarter past year. (INO) is its Earnings per Share or EPS. Relative Strength Index (RSI-14) for Inovio Pharmaceuticals, Inc.

COPYRIGHT VIOLATION WARNING: "Inovio Pharmaceuticals, Inc". The stock has "Buy" rating by H.C. Wainwright on Friday, June 2. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and worldwide copyright & trademark laws. Vanguard Group Inc. raised its stake in Inovio Pharmaceuticals by 7.9% in the first quarter. The rating was upgraded by PiperJaffray to "Overweight" on Thursday, June 8. The short sellers will then buy the stock back at a much lower price and replace the borrowed shares, pocketing the difference. Following the sale, the director now directly owns 740,956 shares of the company's stock, valued at $5,927,648. Also, CEO Jong Joseph Kim sold 147,180 shares of the stock in a transaction that occurred on Friday, March 31st. Its Price to Cash Flow ratio shows the value of 0, whereas, the industry and sector ratio of Price to Cash Flow ticked at 149.08 and 11.95 respectively. The stock was acquired at an average cost of $6.25 per share, with a total value of $133,125.00.

Other reports by GizPress

Discuss This Article